Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influcid
- Development stage
- Phase 4
- Lead developer
- Deutsche Homöopathie-Union
- Administration
- Sublingual, Oral
01
Overview
Influcid is a complex homeopathic medicinal product developed by Deutsche Homöopathie-Union (DHU)-Arzneimittel GmbH & Co. KG. It is indicated for the prevention and treatment of acute upper respiratory tract infections, including influenza and feverish colds. The formulation consists of six active homeopathic ingredients: Aconitum, Bryonia, Ipecacuanha, Gelsemium, Phosphorus, and Eupatorium perfoliatum. Influcid is reported to alleviate typical symptoms such as fever, headache, muscle soreness, rhinitis, and pharyngitis while enhancing the body's natural defenses. Clinical and in vitro studies have suggested that the preparation possesses interferon-inducing activity and broad-spectrum antiviral properties against various respiratory viruses, including influenza A and B, adenoviruses, and coronaviruses. It is available as sublingual tablets and as an oral solution.
- Brand names
- InflucidDHU Influcid
02
Targets
IFNL3 (Interferon lambda 3)
Beyond the preview
Go deeper on Influcid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influcid.